La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Zhejiang Wolwo Bio-Pharmaceutical Crescita futura
Future criteri di controllo 5/6
Zhejiang Wolwo Bio-Pharmaceutical is forecast to grow earnings and revenue by 22.8% and 21.2% per annum respectively. EPS is expected to grow by 22.8% per annum. Return on equity is forecast to be 16.8% in 3 years.
Informazioni chiave
22.8%
Tasso di crescita degli utili
22.8%
Tasso di crescita dell'EPS
Pharmaceuticals crescita degli utili | 18.8% |
Tasso di crescita dei ricavi | 21.2% |
Rendimento futuro del capitale proprio | 16.8% |
Copertura analitica | Low |
Ultimo aggiornamento | 10 Jun 2024 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Has Announced That Its Dividend Will Be Reduced To CN¥0.185
Jun 30Investor Optimism Abounds Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) But Growth Is Lacking
May 27Calculating The Fair Value Of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357)
May 07Is Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) A Risky Investment?
Mar 22Previsioni di crescita degli utili e dei ricavi
Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
---|---|---|---|---|---|
12/31/2026 | 1,582 | 599 | 419 | 532 | 3 |
12/31/2025 | 1,309 | 493 | 298 | 468 | 4 |
12/31/2024 | 1,045 | 390 | 165 | 303 | 3 |
3/31/2024 | 881 | 317 | 145 | 342 | N/A |
12/31/2023 | 848 | 310 | 155 | 382 | N/A |
9/30/2023 | 870 | 292 | 117 | 362 | N/A |
6/30/2023 | 893 | 316 | 74 | 358 | N/A |
3/31/2023 | 882 | 328 | 139 | 389 | N/A |
1/1/2023 | 896 | 349 | 160 | 360 | N/A |
9/30/2022 | 888 | 391 | 199 | 369 | N/A |
6/30/2022 | 849 | 372 | 268 | 385 | N/A |
3/31/2022 | 841 | 359 | 183 | 316 | N/A |
12/31/2021 | 808 | 338 | 236 | 361 | N/A |
9/30/2021 | 765 | 324 | 200 | 307 | N/A |
6/30/2021 | 724 | 319 | 183 | 276 | N/A |
3/31/2021 | 691 | 308 | 218 | 288 | N/A |
12/31/2020 | 636 | 278 | 186 | 256 | N/A |
9/30/2020 | 630 | 281 | 183 | 267 | N/A |
6/30/2020 | 624 | 275 | 155 | 251 | N/A |
3/31/2020 | 612 | 274 | 142 | 252 | N/A |
12/31/2019 | 639 | 298 | 129 | 233 | N/A |
9/30/2019 | 615 | 290 | 120 | 232 | N/A |
6/30/2019 | 556 | 259 | 134 | 227 | N/A |
3/31/2019 | 532 | 247 | 124 | 197 | N/A |
12/31/2018 | 501 | 233 | 144 | 206 | N/A |
9/30/2018 | 478 | 227 | 137 | 173 | N/A |
6/30/2018 | 439 | 211 | 142 | 169 | N/A |
3/31/2018 | 411 | 200 | 149 | 178 | N/A |
12/31/2017 | 386 | 186 | N/A | 159 | N/A |
9/30/2017 | 367 | 175 | N/A | 150 | N/A |
6/30/2017 | 344 | 154 | N/A | 137 | N/A |
3/31/2017 | 324 | 139 | N/A | 128 | N/A |
12/31/2016 | 312 | 129 | N/A | 123 | N/A |
9/30/2016 | 303 | 129 | N/A | 127 | N/A |
6/30/2016 | 283 | 121 | N/A | 116 | N/A |
3/31/2016 | 277 | 122 | N/A | 121 | N/A |
12/31/2015 | 267 | 118 | N/A | 115 | N/A |
9/30/2015 | 261 | 116 | N/A | 107 | N/A |
6/30/2015 | 252 | 112 | N/A | 110 | N/A |
3/31/2015 | 247 | 110 | N/A | 101 | N/A |
12/31/2014 | 240 | 100 | N/A | 84 | N/A |
9/30/2014 | 228 | 90 | N/A | 75 | N/A |
6/30/2014 | 211 | 78 | N/A | 62 | N/A |
3/31/2014 | 202 | 68 | N/A | 59 | N/A |
12/31/2013 | 194 | 71 | N/A | 58 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: 300357's forecast earnings growth (22.8% per year) is above the savings rate (2.9%).
Guadagni vs Mercato: 300357's earnings (22.8% per year) are forecast to grow faster than the CN market (21.9% per year).
Guadagni ad alta crescita: 300357's earnings are expected to grow significantly over the next 3 years.
Ricavi vs Mercato: 300357's revenue (21.2% per year) is forecast to grow faster than the CN market (13.4% per year).
Ricavi ad alta crescita: 300357's revenue (21.2% per year) is forecast to grow faster than 20% per year.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: 300357's Return on Equity is forecast to be low in 3 years time (16.8%).